evidencegaps
Search

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

51 questions · 51 findings · 1 reviews · Schizophrenia

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 3 · 5.9%GRADE not reported 10 · 19.6%Very low 11 · 21.6%Low 17 · 33.3%Moderate 10 · 19.6%High 0 · 0%

RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS

Adverse events: Specific ‐ prolactin‐related ‐ long term It is unclear how adverse events were reported · patients with schizophrenia

It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Specific ‐ prolactin‐related ‐ long term It is… compared with GENERAL ORAL ANTIPSYCHOTICS (very low certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS

Weight gain · patients with schizophrenia

It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Specific ‐ weight increase ‐ long term It is unclear… compared with GENERAL ORAL ANTIPSYCHOTICS (very low certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS

Adverse events: Nervous system disorders (inc. EPS) ‐ long term It is unclear how adverse events were reported · patients with schizophrenia

It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Nervous system disorders (inc. EPS) ‐ long term It… compared with GENERAL ORAL ANTIPSYCHOTICS (very low certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs RISPERIDONE

Behaviour: Leaving the study early (short‐term) · patients with schizophrenia

RISPERIDONE DEPOT showed no clear difference in leaving the study early: Any reason ‐ short term compared with ORAL RISPERIDONE (moderate certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs RISPERIDONE

Adverse events: Movement disorder ‐ any extra pyramidal symptoms ‐ short term · patients with schizophrenia

RISPERIDONE DEPOT showed no clear difference in adverse events: Movement disorder ‐ any extra pyramidal symptoms ‐… compared with ORAL RISPERIDONE (moderate certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs RISPERIDONE

Adverse events: Specific ‐ prolactin‐related · patients with schizophrenia

RISPERIDONE DEPOT showed no clear difference in adverse events: Specific ‐ prolactin‐related compared with ORAL RISPERIDONE (moderate certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs placebo

Mental state: clinically significant improvement in mental state ‐ long term1 ‐ not reported · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

RISPERIDONE DEPOT vs QUETIAPINE

Leaving the study early · patients with schizophrenia

RISPERIDONE DEPOT probably leads to lower leaving the study early: Any reason ‐ long term compared with ORAL QUETIAPINE (moderate certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs QUETIAPINE

Adverse events: General ‐ serious · patients with schizophrenia

RISPERIDONE DEPOT showed no clear difference in adverse events: General ‐ serious Recorded at each compared with ORAL QUETIAPINE (low certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs QUETIAPINE

Adverse events: Movement disorder ‐ any extra pyramidal symptom · patients with schizophrenia

RISPERIDONE DEPOT may leads to higher adverse events: Movement disorder ‐ any extra pyramidal symptom compared with ORAL QUETIAPINE (low certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs QUETIAPINE

Adverse events: Specific ‐ prolactin‐related · patients with schizophrenia

RISPERIDONE DEPOT may leads to higher adverse events: Specific ‐ prolactin‐related Reported by… compared with ORAL QUETIAPINE (low certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs ARIPIPRAZOLE

Relapse · patients with schizophrenia

RISPERIDONE DEPOT showed no clear difference in global state: Relapse (any reason) ‐ long term Assessed by 5 blinded… compared with ORAL ARIPIPRAZOLE (low certainty).

1 finding from 1 review